Clinical

A new treatment using human immune cells can prevent infections in patients with leukemia who have a weakened immune system due to treatment for their disease.

A survey of global physicians found a gap in knowledge of non-alcoholic fatty liver disease (NAFLD) despite the growing burden of the disease worldwide.

The nationwide, population-based study analyzed data on over 1900 patients with primary myelofibrosis (pMF), comparing rates of survival from 2001-2010 with 2011-2018.

Different ulcer wound treatments were analyzed in elderly patients with multiple medical conditions, revealing that a multidisciplinary approach may be needed to ensure efficacy.

A database of information about more than 30,000 patients verified improved morbidity and mortality due to vaccines and preventive health care in prospective trials.

The more often a patient used systemic corticosteroids, the higher their risk of moderate or severe COVID-19 and all-cause mortality, the study found.

Based on subgroup analyses of over 500 younger patients with intermediate-risk disease, the researchers say measurable residual disease (MRD)-guided decisions may help achieve better outcomes postremission.

Based on difference-in-difference (DID) analysis, genomics-informed treatment increased time to treatment discontinuation by an estimated 3 months and increased costs by an estimated C$90,000—equivalent to approximately US$72,000—compared with standard care treatment.

No clinical or genetic markers were found to be predictive of psoriatic arthritis in patients with psoriasis, but one laboratory marker was identified.

In part 7 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed telehealth and the role of remote care.

In part 6 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed examples of game-changing therapy in cancer care.

In part 5 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed why AccessHope offers an option to payers and oncologists.

In part 4 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed how the therapeutic pipeline has changed.

In part 3 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed the payer perspective in the rise of genomics.

In part 2 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed how genomics have changed the cancer care landscape.

In the latest Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed designing genomic testing in cancer care.

A new study says that treating iron deficiency therapy may improve outcomes in patients with chronic kidney disease, even if they don’t have anemia.

In a recent review, researchers describe what is currently known about allogenic hemopoietic stem cell transplant (HSCT) for myelofibrosis.

Posters presented at the European Hematology Association 2021 Virtual Congress evaluated acute myeloid leukemia (AML) in elderly patients.

A long-term Swedish study found that nonalcoholic fatty liver disease (NALFD) significantly increased mortality in children and young adults, particularly due to cancer, cardiometabolic disease, and liver disease.

Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.

A retrospective analysis of real-world data found a discrepancy between actual care and the recommendations from clinical trials for patients with mantle cell lymphoma, resulting in outcomes that were worse than in trials.

The findings, say the researchers, highlight a need for prognostic models specific to patients with prefibrotic primary myelofibrosis (pre-PMF).

Years of research has shown that in cancers like melanoma, liquid biopsy enables the detection of biomarkers, such as circulating tumor cells, circulating tumor DNA, and exomes.

Manipulating the expression of MAGEA3 can help block the growth of hepatocellular carcinoma.